Advertisement
U.S. markets open in 4 hours 37 minutes

Fortress Biotech, Inc. (FBIOP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
16.77+0.28 (+1.70%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close16.49
Open16.31
Bid14.60 x 1100
Ask16.50 x 800
Day's Range16.31 - 16.95
52 Week Range6.40 - 18.91
Volume7,207
Avg. Volume12,785
Market Cap90.019M
Beta (5Y Monthly)1.51
PE Ratio (TTM)N/A
EPS (TTM)-0.86
Earnings DateN/A
Forward Dividend & Yield2.34 (13.98%)
Ex-Dividend DateMar 14, 2024
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for FBIOP

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Fortress Biotech, Inc. - 9.375%
    JAZZ: Lowering target price to $124.00JAZZ PHARMACEUTICALS PLC has an Investment Rating of HOLD; a target price of $124.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • GlobeNewswire

    Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024

    MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will host a virtual key opinion leader (“KOL”) event highlighting expert perspectives on spinal bulbar muscular atrophy (“SBMA”), also known as Kennedy's Disease, on Thursday, April 4, 2024 at 11:00am ET. The virtual event wi

  • GlobeNewswire

    Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

    WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2023, and recent corporate highlights. James F. Oliviero, President and Chief Executive Officer of Checkpoint, said, “We continue to work closely with our third-party contract manufacturing organization to expeditiously resolve the deficiencies noted in t

  • GlobeNewswire

    Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

    Company generated total revenues of $79.2 million for the full year ended December 31, 2023, a 7% increase from the $73.7 million reported in 2022 Achieved $15.6 million in operating cost savings in 2023, ahead of initial guidance of $12.0 million New Drug Application for rosacea treatment candidate DFD-29 accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDAL